Yan Leyfman: New Insights in Multiple Myeloma Care
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New insights in multiple myeloma care
A new study led by Dr. Lekha Mikkilineni (Stanford Medicine Cancer Center) sheds light on how CD38 monoclonal antibody (mAb)-based induction impacts stem cell mobilization in newly diagnosed multiple myeloma (NDMM) patients undergoing autologous stem cell transplant (ASCT).
Key findings:
9.4% lower stem cell yield with CD38 mAb exposure
More plerixafor use and additional apheresis sessions needed
$23K higher mobilization costs per patient
Longer washout periods improved yields, highlighting a modifiable factor
Why this matters:
As CD38 mAbs (e.g., daratumumab, isatuximab) become standard in frontline NDMM regimens, understanding their downstream impact on ASCT is essential. These findings underscore the importance of tailoring mobilization strategies and optimizing washout timing to improve efficiency, cost-effectiveness, and patient outcomes.”
Title: The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024
Authors: Dilek Uzun, Jeddeo Michael Paul, Alexandria Jensen, John Tamaresis, Walter Domingo, Sally Arai, Felipe Araya Ventura, Jennifer Rocha, Leslie Bennett, Amelia Jones, Sushma Bharadwaj, Laura Johnston, Robert Lowsky, Andrew Rezvani, Parveen Shiraz, Judith Shizuru, Wen-Kai Weng, Hitomi Hosoya, Surbhi Sidana, David Miklos, Lekha Mikkilineni
Read the Full Article.
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023